✦ LIBER ✦

Second-line therapy for non-small cell lung cancer in clinical practice: final results and treatment pathways from the SELECTTION observational study

✍ Scribed by Vergnenegre, Alain; Smit, Egbert F.; Toy, Elisabeth; Parente, Barbara; Schmitz, Stephan; Kraaij, Kees; Soldatenkova, Victoria; Visseren-Grul, Carla; Zanotti, Giovanni; Taipale, Kaisa; Moro-Sibilot, Denis

Book ID: 126553649
Publisher: Informa plc
Year: 2012
Tongue: English
Weight: 407 KB
Volume: 28
Category: Article
ISSN: 0300-7995
DOI: 10.1185/03007995.2012.703133

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A multicentre prospective study on pemet

A multicentre prospective study on pemetrexed in the second line chemotherapy of non small cell lung cancer. Data from routine clinical practice

✍ Kolek, Vítězslav; Pešek, Miloš; Grygárková, Ivona; Zatloukal, Petr; Skřičková, J 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Biomarker Analyses and Final Overall Sur

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)

✍ Fukuoka, M.; Wu, Y.-L.; Thongprasert, S.; Sunpaweravong, P.; Leong, S.-S.; Sriur 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 241 KB

PCN32 COST-MINIMISATION ANALYSIS OF ERLO

PCN32 COST-MINIMISATION ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL OR PEMETREXEDAS SECOND-LINE THERAPY FOR NON-SMALL-CELL LUNG CANCER (NSCLC) FROM THE PERSPECTIVE OF A PRIVATE PAYER IN BRAZIL

✍ S Stefani; MG Saggia; EA Santos 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

Pemetrexed Versus Pemetrexed and Carbopl

Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial

✍ Ardizzoni, A.; Tiseo, M.; Boni, L.; Vincent, A. D.; Passalacqua, R.; Buti, S.; A 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 200 KB

PD-147 A phase I study of a second gener

PD-147 A phase I study of a second generation antisenseoligonucleotide to clusterin (OGX-011) in combination with gemcitabine and cisplatin as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC): Preliminary results

✍ Laskin, J.; Chi, K.; Melosky, B.; Sill, K.; Hao, D.; Canil, C.; Gleave, M.; Murr 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 129 KB

3529 POSTER Effect of Sample Type and Tu

3529 POSTER Effect of Sample Type and Turnaround Time (TAT) on the Feasibility of Non-Small Cell Lung Cancer (NSCLC) Epidermal Growth Factor Receptor (EGFR) Mutation Testing in Routine Clinical Practice: Results From the Spanish REASON Study

✍ M. Gracia; M. Majem; M.T. Martinez Aguillo; N. Martinez Banaclocha; M. Provencio 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 41 KB